Arkolith/Insider Trading/RPRX/Form 4

Urist Marshall

EVP, Research & InvestmentsRoyalty Pharma plc (RPRX) · full profile →Form 4 · filed Jun 25, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$502K
Net Open-Market Flow
-$502K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 24, 2026Sell(S)9K$55.18$502K9K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001838139-26-000020) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML